Evidence map›Paper›PMID 39845956›Full record

ReviewFrontiers in immunology2024

The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis.

Marco Puthenparampil, Marta Gaggiola, Francesca Rinaldi, M Nosadini, S Sartori, Paola Perini, Paolo Gallo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marco PuthenparampilDepartment of Neurosciences, University of Padua, Padua, Italy.
Marta GaggiolaDepartment of Neurosciences, University of Padua, Padua, Italy.
Francesca RinaldiMultiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy.
M NosadiniImmune-Mediated Nervous System Disease Study Group, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy.
S SartoriImmune-Mediated Nervous System Disease Study Group, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy.
Paola PeriniMultiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy.
Paolo GalloDepartment of Neurosciences, University of Padua, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests that the use of induction therapies, including alemtuzumab (ALTZ), might be a promising approach, at least for postpuberal (> 11 yo) POMS. Although no data on the use of induction therapies in POMS are available from clinical trials currently, case series or case reports on the effect of alemtuzumab (ALTZ) have been recently published. In this review we have briefly revised the immunopathogenic features of POMS, as well as on how ALTZ might impact on them, reporting its efficacy observed in different POMS cohorts.

Indexed as

AlemtuzumabMultiple SclerosisAge of OnsetChildHumansTreatment OutcomeAlemtuzumabalemtuzumabinduction therapymultiple sclerosispediatric-onset MSPOMS

Identifiers

PMID39845956
PMCPMC11750650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.